RAD54L

DNA repair and recombination protein RAD54-like · Q92698 · RAD54L on Sugi Atlas →

35 patent compounds predicted against RAD54L, 29 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Streptonigrin (SCHEMBL3940)	1.00	1/20
Streptonigrin (SCHEMBL29371276)	1.00	1/20
Streptonigrin (SCHEMBL29374011)	1.00	1/20
Streptonigrin (SCHEMBL29821157)	1.00	1/20
Streptonigrin (SCHEMBL4636734)	0.88	1/20
SCHEMBL25015126	0.87	1/20
SCHEMBL30260509	0.87	1/20
Streptonigrin (SCHEMBL23421492)	0.85	1/20
Streptonigrin (SCHEMBL6299739)	0.84	1/20
SCHEMBL23484220	0.80	1/20
SCHEMBL20257205	0.75	1/20
SCHEMBL29885591	0.70	1/20
SCHEMBL23484180	0.69	1/20
SCHEMBL13996269	0.68	1/20
Streptonigrin (SCHEMBL14893253)	0.66	1/20
SCHEMBL20250622	0.64	1/20
Imidazoquinoline (SCHEMBL29371586)	0.62	1/20
SCHEMBL21801928	0.49	1/20
SCHEMBL21801909	0.48	1/20
SCHEMBL21801927	0.48	1/20

Clinical trials — most relevant to RAD54L by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)	PHASE2	RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)	PHASE2	COMPLETED
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation	PHASE2	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors	PHASE2	COMPLETED
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency	PHASE2	RECRUITING
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer	PHASE2	UNKNOWN
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations	PHASE2	RECRUITING
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	PHASE2	COMPLETED
Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations	PHASE2	COMPLETED
Niraparib and Dostarlimab in HRD Solid Tumors	PHASE2	UNKNOWN
Niraparib in Tumors Metastatic to the CNS	PHASE2	ACTIVE_NOT_RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA	PHASE2	ACTIVE_NOT_RECRUITING
The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation	PHASE2	UNKNOWN
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	PHASE1	RECRUITING
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)	nan	RECRUITING
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Precision-Based Genomics in Prostate Cancer	nan	RECRUITING
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RAD54L binder may also engage these)

Protein	Name	Similarity
P70270	—	1.000	P70270 →
O12944	—	1.000	O12944 →
F1Q8K0	—	1.000	F1Q8K0 →
B3NAN8	—	0.999	B3NAN8 →
O76460	—	0.997	O76460 →
B4NXB8	—	0.995	B4NXB8 →
B3MMA5	—	0.995	B3MMA5 →
Q9CXF7	—	0.994	Q9CXF7 →
Q9Y4B4	—	0.994	Q9Y4B4 →
B4MX21	—	0.993	B4MX21 →
Q0PCS3	—	0.992	Q0PCS3 →
Q7ZU90	—	0.992	Q7ZU90 →
B4M9A8	—	0.992	B4M9A8 →
Q29KH2	—	0.992	Q29KH2 →
Q99NG0	—	0.991	Q99NG0 →
POLQ	DNA polymerase theta	0.990	landscape →
B4KHL5	—	0.990	B4KHL5 →
Q0DLB9	—	0.990	Q0DLB9 →
B6ZLK2	—	0.989	B6ZLK2 →
B4GS98	—	0.989	B4GS98 →
CHD1L	Chromodomain-helicase-DNA-binding protein 1-like	0.989	landscape →
Q3B7N1	—	0.989	Q3B7N1 →
B5VE38	—	0.989	B5VE38 →
D3ZA12	—	0.989	D3ZA12 →
P41410	—	0.988	P41410 →
A3KFM7	—	0.988	A3KFM7 →
F4IV45	—	0.988	F4IV45 →
B4JCS7	—	0.987	B4JCS7 →
CHD1	Chromodomain-helicase-DNA-binding protein 1	0.987	landscape →
Q8BJL0	—	0.987	Q8BJL0 →